Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Nivolumab in dMMR/MSI Colorectal and Gastric Cancers
NCT07542262Phase 2Enrolling by invitation
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in colorectal cancer (CRC), gastric cancer (GC), sponsored by N.N. Blokhin Russian Cancer Research Center. Started Jun 2025; status: enrolling by invitation.
02
Drugs
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT07542262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542262.